[{"external_id":{"pmid":["36371895"]},"date_updated":"2024-10-14T12:34:11Z","extern":"1","_id":"15132","abstract":[{"lang":"eng","text":"Clustered regularly interspaced short palindromic repeats - CRISPR-associated protein (CRISPR-Cas) systems are a critical component of the bacterial adaptive immune response. Since the discovery that they can be reengineered as programmable RNA-guided nucleases, there has been significant interest in using these systems to perform diverse and precise genetic manipulations. Here, we outline recent advances in the mechanistic understanding of CRISPR-Cas9, how these findings have been leveraged in the rational redesign of Cas9 variants with altered activities, and how these novel tools can be exploited for biotechnology and therapeutics. We also discuss the potential of the ubiquitous, yet often-overlooked, multisubunit CRISPR effector complexes for large-scale genomic deletions. Furthermore, we highlight how future structural studies will bolster these technologies."}],"intvolume":"        78","article_type":"review","month":"12","keyword":["Biomedical Engineering","Bioengineering","Biotechnology"],"volume":78,"publication":"Current Opinion in Biotechnology","citation":{"apa":"Bravo, J. P. K., Hibshman, G. N., &#38; Taylor, D. W. (2022). Constructing next-generation CRISPR–Cas tools from structural blueprints. <i>Current Opinion in Biotechnology</i>. Elsevier. <a href=\"https://doi.org/10.1016/j.copbio.2022.102839\">https://doi.org/10.1016/j.copbio.2022.102839</a>","ista":"Bravo JPK, Hibshman GN, Taylor DW. 2022. Constructing next-generation CRISPR–Cas tools from structural blueprints. Current Opinion in Biotechnology. 78, 102839.","mla":"Bravo, Jack Peter Kelly, et al. “Constructing Next-Generation CRISPR–Cas Tools from Structural Blueprints.” <i>Current Opinion in Biotechnology</i>, vol. 78, 102839, Elsevier, 2022, doi:<a href=\"https://doi.org/10.1016/j.copbio.2022.102839\">10.1016/j.copbio.2022.102839</a>.","chicago":"Bravo, Jack Peter Kelly, Grace N Hibshman, and David W Taylor. “Constructing Next-Generation CRISPR–Cas Tools from Structural Blueprints.” <i>Current Opinion in Biotechnology</i>. Elsevier, 2022. <a href=\"https://doi.org/10.1016/j.copbio.2022.102839\">https://doi.org/10.1016/j.copbio.2022.102839</a>.","ieee":"J. P. K. Bravo, G. N. Hibshman, and D. W. Taylor, “Constructing next-generation CRISPR–Cas tools from structural blueprints,” <i>Current Opinion in Biotechnology</i>, vol. 78. Elsevier, 2022.","short":"J.P.K. Bravo, G.N. Hibshman, D.W. Taylor, Current Opinion in Biotechnology 78 (2022).","ama":"Bravo JPK, Hibshman GN, Taylor DW. Constructing next-generation CRISPR–Cas tools from structural blueprints. <i>Current Opinion in Biotechnology</i>. 2022;78. doi:<a href=\"https://doi.org/10.1016/j.copbio.2022.102839\">10.1016/j.copbio.2022.102839</a>"},"article_number":"102839","user_id":"2DF688A6-F248-11E8-B48F-1D18A9856A87","quality_controlled":"1","doi":"10.1016/j.copbio.2022.102839","publication_identifier":{"issn":["0958-1669"]},"date_published":"2022-12-01T00:00:00Z","type":"journal_article","day":"01","language":[{"iso":"eng"}],"scopus_import":"1","year":"2022","author":[{"orcid":"0000-0003-0456-0753","full_name":"Bravo, Jack Peter Kelly","first_name":"Jack Peter Kelly","id":"96aecfa5-8931-11ee-af30-aa6a5d6eee0e","last_name":"Bravo"},{"last_name":"Hibshman","first_name":"Grace N","full_name":"Hibshman, Grace N"},{"full_name":"Taylor, David W","first_name":"David W","last_name":"Taylor"}],"pmid":1,"oa_version":"None","title":"Constructing next-generation CRISPR–Cas tools from structural blueprints","article_processing_charge":"No","publication_status":"published","publisher":"Elsevier","date_created":"2024-03-20T10:41:53Z","status":"public"},{"publication_status":"published","publisher":"Elsevier","acknowledgement":"This work was supported by grants of the European Union Seventh Framework Programme (CIG-303564), the Human Frontier Science Program (RGY0084_2012), and the Austrian Science Fund FWF (W1232 MolecularDrugTargets).","date_created":"2018-12-11T11:49:45Z","status":"public","project":[{"name":"In situ real-time imaging of neurotransmitter signaling using designer optical sensors","grant_number":"RGY0084/2012","_id":"255BFFFA-B435-11E9-9278-68D0E5697425"},{"grant_number":"303564","name":"Microbial Ion Channels for Synthetic Neurobiology","call_identifier":"FP7","_id":"25548C20-B435-11E9-9278-68D0E5697425"},{"grant_number":"W1232-B24","name":"Molecular Drug Targets","_id":"255A6082-B435-11E9-9278-68D0E5697425","call_identifier":"FWF"}],"author":[{"full_name":"Agus, Viviana","first_name":"Viviana","last_name":"Agus"},{"orcid":"0000-0002-8023-9315","last_name":"Janovjak","id":"33BA6C30-F248-11E8-B48F-1D18A9856A87","full_name":"Janovjak, Harald L","first_name":"Harald L"}],"year":"2017","title":"Optogenetic methods in drug screening: Technologies and applications","article_processing_charge":"No","ec_funded":1,"oa_version":"None","day":"01","page":"8 - 14","type":"journal_article","isi":1,"language":[{"iso":"eng"}],"scopus_import":"1","date_published":"2017-12-01T00:00:00Z","doi":"10.1016/j.copbio.2017.02.006","publication_identifier":{"issn":["0958-1669"]},"publist_id":"6365","citation":{"ieee":"V. Agus and H. L. Janovjak, “Optogenetic methods in drug screening: Technologies and applications,” <i>Current Opinion in Biotechnology</i>, vol. 48. Elsevier, pp. 8–14, 2017.","apa":"Agus, V., &#38; Janovjak, H. L. (2017). Optogenetic methods in drug screening: Technologies and applications. <i>Current Opinion in Biotechnology</i>. Elsevier. <a href=\"https://doi.org/10.1016/j.copbio.2017.02.006\">https://doi.org/10.1016/j.copbio.2017.02.006</a>","mla":"Agus, Viviana, and Harald L. Janovjak. “Optogenetic Methods in Drug Screening: Technologies and Applications.” <i>Current Opinion in Biotechnology</i>, vol. 48, Elsevier, 2017, pp. 8–14, doi:<a href=\"https://doi.org/10.1016/j.copbio.2017.02.006\">10.1016/j.copbio.2017.02.006</a>.","ista":"Agus V, Janovjak HL. 2017. Optogenetic methods in drug screening: Technologies and applications. Current Opinion in Biotechnology. 48, 8–14.","chicago":"Agus, Viviana, and Harald L Janovjak. “Optogenetic Methods in Drug Screening: Technologies and Applications.” <i>Current Opinion in Biotechnology</i>. Elsevier, 2017. <a href=\"https://doi.org/10.1016/j.copbio.2017.02.006\">https://doi.org/10.1016/j.copbio.2017.02.006</a>.","ama":"Agus V, Janovjak HL. Optogenetic methods in drug screening: Technologies and applications. <i>Current Opinion in Biotechnology</i>. 2017;48:8-14. doi:<a href=\"https://doi.org/10.1016/j.copbio.2017.02.006\">10.1016/j.copbio.2017.02.006</a>","short":"V. Agus, H.L. Janovjak, Current Opinion in Biotechnology 48 (2017) 8–14."},"user_id":"ba8df636-2132-11f1-aed0-ed93e2281fdd","quality_controlled":"1","intvolume":"        48","_id":"1026","abstract":[{"text":"The optogenetic revolution enabled spatially-precise and temporally-precise control over protein function, signaling pathway activation, and animal behavior with tremendous success in the dissection of signaling networks and neural circuits. Very recently, optogenetic methods have been paired with optical reporters in novel drug screening platforms. In these all-optical platforms, light remotely activated ion channels and kinases thereby obviating the use of electrophysiology or reagents. Consequences were remarkable operational simplicity, throughput, and cost-effectiveness that culminated in the identification of new drug candidates. These blueprints for all-optical assays also revealed potential pitfalls and inspire all-optical variants of other screens, such as those that aim at better understanding dynamic drug action or orphan protein function.","lang":"eng"}],"month":"12","article_type":"original","volume":48,"publication":"Current Opinion in Biotechnology","department":[{"_id":"HaJa"}],"date_updated":"2026-04-16T09:57:03Z","external_id":{"isi":["000418313200003"]},"corr_author":"1"}]